Drug Approval | March 06, 2023
Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of US $233.7 mn in US
Vigabatrin for Oral Solution USP, 500 mg had annual sales of USD 233.7 mn in the United States
The product will be manufactured at Lupin’s facility in Goa, India
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
Subscribe To Our Newsletter & Stay Updated
